These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39013658)

  • 1. Assessing a Suitable Radiotherapy Utilisation Benchmark for Older Patients With Head and Neck Cancer.
    Mackenzie P; Vajdic C; Delaney G; Comans T; Agar M; Gabriel G; Barton M
    Clin Oncol (R Coll Radiol); 2024 Oct; 36(10):e381-e387. PubMed ID: 39013658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting radiotherapy utilisation in geriatric oncology patients in NSW, Australia.
    Mackenzie P; Vajdic C; Delaney G; Gabriel G; Agar M; Comans T; Barton M
    Tech Innov Patient Support Radiat Oncol; 2020 Dec; 16():17-23. PubMed ID: 33385070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an age- and comorbidity- adjusted optimal radiotherapy utilisation rate for lung, rectal, prostate and cervical cancers.
    Mackenzie P; Vajdic C; Delaney G; Comans T; Agar M; Gabriel G; Barton M
    Radiother Oncol; 2023 Nov; 188():109862. PubMed ID: 37619661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an age- and comorbidity adjusted- optimal radiotherapy utilisation rate for women with breast cancer.
    Mackenzie P; Vajdic C; Delaney G; Comans T; Agar M; Gabriel G; Barton M
    J Geriatr Oncol; 2022 Jul; 13(6):844-849. PubMed ID: 35514015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy utilisation rates for patients with cancer as a function of age: A systematic review.
    Mackenzie P; Vajdic C; Delaney G; Comans T; Morris L; Agar M; Gabriel G; Barton M
    J Geriatr Oncol; 2023 Apr; 14(3):101387. PubMed ID: 36272958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia.
    Batumalai V; Shafiq J; Gabriel G; Hanna TP; Delaney GP; Barton M
    Radiother Oncol; 2018 Nov; 129(2):191-195. PubMed ID: 29983259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provincial variations in radiotherapy utilization as a measure of access: A pan-Canadian study.
    Chan J; Brown E; Dennis K; Milosevic M; Brundage M
    Radiother Oncol; 2022 Feb; 167():122-126. PubMed ID: 34942281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy utilization in developing countries: An IAEA study.
    Rosenblatt E; Fidarova E; Zubizarreta EH; Barton MB; Jones GW; Mackillop WJ; Cordero L; Yarney J; Lim G; Gan JV; Cernea V; Stojanovic-Rundic S; Strojan P; Kochbati L; Quarneti A
    Radiother Oncol; 2018 Sep; 128(3):400-405. PubMed ID: 29859755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of investment in radiotherapy in New South Wales: why does the gap between optimal and actual persist?
    Barton MB; Delaney GP
    J Med Imaging Radiat Oncol; 2011 Aug; 55(4):433-41. PubMed ID: 21843180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actual Versus Optimal Radiotherapy Utilisation for Metastatic Cancer Patients in the 45 and Up Study Cohort, New South Wales.
    Yap ML; O'Connell DL; Goldsbury DE; Weber MF; Barton MB
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):650-660. PubMed ID: 33750600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
    Saraswathula A; Chen MM; Colevas AD; Divi V
    JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1160-1167. PubMed ID: 31621810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
    Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.
    Delaney G; Jacob S; Barton M
    Cancer; 2005 Jun; 103(11):2216-27. PubMed ID: 15856428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective survey of radiotherapy in Sweden.
    Acta Oncol; 1996; 35 Suppl 6():47-56. PubMed ID: 9154085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of travel distance on radiotherapy utilization in NSW and ACT.
    Gabriel G; Barton M; Delaney GP
    Radiother Oncol; 2015 Nov; 117(2):386-9. PubMed ID: 26243679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
    Fu KK; Pajak TF; Marcial VA; Ortiz HG; Rotman M; Asbell SO; Coia LR; Vora NL; Byhardt R; Rubin P
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):577-88. PubMed ID: 7790242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly.
    Haehl E; Rühle A; Klink R; Kalckreuth T; Sprave T; Gkika E; Zamboglou C; Meiß F; Grosu AL; Nicolay NH
    Radiat Oncol; 2021 Jun; 16(1):105. PubMed ID: 34118984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.